Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the safety, tolerability, and antiviral efficacy of
ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) with or without ribavirin (RBV),
administered for 8 or 12 weeks of treatment in participants with chronic genotype 1 hepatitis
C virus (HCV) infection who are treatment-naive, and for 12 weeks in participants who had
previously received a regimen containing a protease inhibitor for the treatment of HCV.
Phase:
Phase 2
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Ledipasvir, sofosbuvir drug combination Protease Inhibitors Ribavirin Sofosbuvir